Safety and dose study of a new hepatitis B vaccine in healthy adults
Part of Digestive system, Infections clinical trials.
This study is testing a new hepatitis B vaccine called SN2001 in healthy adults. It will check how safe the vaccine is, what dose works best, and how well it helps your body build protection against hepatitis B.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are in good general health, without serious medical conditions like diabetes, heart disease, or a weak immune system.
- You have not had a hepatitis B vaccine before, or if you have, it's been more than 6 months and your antibody levels are low.
- You are not pregnant, breastfeeding, or planning to get pregnant during the study.
- You have not been in another drug or vaccine study in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug called AHB-171 for people with chronic hepatitis B who are already stable on standard antiviral therapy. It aims to see if the drug is safe and may help control the virus better.
This study tests a new injection called IB-001 in two groups: healthy people and people with chronic hepatitis B. The goal is to see if it's safe and how the body handles it at different doses. It might offer a new treatment option for hepatitis B in the future.
Doctors are testing a new injectable treatment for chronic hepatitis B. This first-in-human study checks the drug's safety and how well it works in people who are already on standard hepatitis B pills.
This trial tests an experimental vaccine therapy to help control or possibly cure chronic hepatitis B. It is designed to see whether the treatment is safe and how well it affects the hepatitis B virus in adults.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
This trial tests a new medication called ACT201 in two parts: one for healthy volunteers and one for people with chronic hepatitis B. For participants with hepatitis B, the drug may help control the infection, and the study will check its safety and how well it works.
Hear when a new Chronic Hepatitis B Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.